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Summary The kinetics, specificity and morphology of cytolethal responses have been studied in human
glucocorticoid-sensitive and -insensitive lymphoid cell lines (HLCL) and fibroblasts following treatment with
high (10-3M) and low (10-6M) doses of steroid. The high dose cytolethal response appears non-specific
occurring in all cell lines with every steroid tested. By contrast, the low dose (pharmacological) cytolethal
response requires an active glucocorticoid and a sensitive HLCL. However, both high and low concentrations
of steroid induce virtually identical morphological changes in dying cells and similar changes can be induced
in cells killed by deliberate feed exhaustion. Although the morphological features in each case resemble
apoptosis, the "programmed" physiological form of cell death, the intracellular events leading to cytolysis
seem likely to differ. The earliest morphological changes presaging cell death comprise rounding up of cells
and condensation of nuclear chromatin. Nuclear changes progress rapidly thereafter and appear to result
from detachment of chromatin from the nuclear matrix. The low dose cytolethal response requires the
continuous presence of glucocorticoid for periods in excess of 24h, prior to which cell growth appears
unaffected. The constancy of this latent interval suggests glucocorticoids may influence some replication
control mechanism unrelated initially to macromolecular biosynthesis.
Although glucocorticoid hormones are used
extensively for treatment of human leukaemias and
lymphomas (Schein et al., 1975; Simone, 1981) their
therapeutic mode of action in man has still to be
resolved. To elucidate the mechanisms involved
human lymphoid cell lines (HLCL) have been
employed as in vitro models for studies of
glucocorticoid effects. However, unlike rodent
thymocytes and lymphoid cell lines, HLCL are
relatively resistant to the lethal actions of
glucocorticoids and frequently require massive
suprapharmacological concentrations of hormone
to produce significant cytolethal responses (Bird et
al., 1977; Burrow et al., 1981; Barrett et al., 1981).
Recently more sensitive HLCL have become
available for investigation where cytolethal effects
may be induced by lower, therapeutically attainable
concentrations of hormone (Norman & Thompson,
1977).
Previously we described the morphology of
glucocorticoid-induced cell death in HLCL where
suprapharmacological concentrations of hormone
were applied to relatively resistant HLCL
(Robertson et al., 1978). Certain of the
morphological features observed resembled
apoptosis, the form of cell death occurring in
situations where cell deletion is considered
programmed (Wyllie et al., 1980). We suggested this
might provide a suitable in vitro model for study of
Correspondence: C.C. Bird
Received 22 September 1982; accepted 22 January 1983.
apoptosis. However, the relevance of effects
requiring such massive concentrations of hormone
is questionable and in this paper we present the
results of further studies where we have examined
the effects of high and low doses of glucocorticoid
and other steroids in both sensitive and insensitive
HLCL and a human fibroblast cell line.
Materials and methods
Cell culture
The glucocorticoid-sensitive human lymphoid cell
line CCRF-CEM-C7 (Norman & Thompson, 1977)
was cloned originally from a glucocorticoid-
insensitive line CCRF-CEM established from a
patient with acute lymphoblastic leukaemia (Foley
et al, 1965). The original clone was kindly provided
by Dr. M. Norman, King's College Hospital,
London and has been repeatedly recloned. The
parent glucocorticoid-resistant line (CCRF-CEM)
was used for comparison. Cell lines were grown at
37°C in suspension culture in conical glass flasks or
in plastic test tubes in RPMI 1640 medium
supplemented with 10% heat-inactivated (56°C for
1 h) donor calf serum (Gibco, Paisley, Scotland),
morpholinopropane sulphonic acid buffer (MOPS:
2.62 gl-1; Hopkin and Williams Ltd., Essex,
England) penicillin (100 IU ml-1) and streptomycin
sulphate (100 ,ug ml-1). Human fibroblasts (Flow
1000: Flow Laboratories Ltd., Irvine, Scotland)
were grown in the same medium in Falcon flasks.
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Steroids
Methylprednisolone sodium succinate (MPSS:
Upjohn, England) was dissolved in sterile distilled
water. Prednisone, dexamethasone, triamcinolone,
testosterone and progesterone (Sigma Co., London,
England) and cortexolone and spironolactone
(Steraloids, Croydon, England) were dissolved in
ethanol or dimethyl sulphoxide so that the final
concentration of solvent did not exceed 1% (v/v).
Kinetics lethal response
Duplicate cultures of cells (2ml aliquots) were set
up in plastic test tubes at 0.15-0.2 x 106 viable
cells ml-1. After treatment with steroid, samples
were removed at 48 and 96h for assessment of cell
concentration and viability using a haemocytometer
as judged by the ability of cells to exclude the
supravital dye nigrosine (0.25% w/v). At 48 h
cultures were fed by replacing 0.5ml of medium
with fresh culture medium containing the
appropriate steroid. For pulsed treatment cells were
exposed to steroid for either 3 or 6h at constant
times each day. Termination of steroid treatment
was accomplished by thrice centrifuging cell
suspensions at 100g for 10 min and resuspending
pellets in fresh steroid-free medium.
Light microscopy
Smears of cells were carefully prepared (to minimise
trauma) on glass slides, air dried, fixed in 95%
methanol for 30 min, stained with 4% (v/v),
Giemsa (Gurr's Improved R66, Searle Diagnostic,
England) for 20 min, differentiated in water and
mounted in picolyte resin. On other smears Feulgen
stainiqg was performed employing optimum
hydrolysis (2 min at 60°C) in 4N hydrochloric acid.
Cytospin preparations were made by removing
0.4ml aliquots of cells and centrifuging in a
Shandon cytospin at 600 rpm for 10min. Slides
were fixed and stained as described above. A
further 0.4ml of cell suspension was placed in drop
form on a glass slide without smearing or coverslip.
This suspension was examined immediately by
phase microscopy using an Olympus CK inverted
microscope.
Electron microscopy
Aliquots of cell suspension 5-10 x 106 cells were
centrifuged at 100 g for 10min at room
temperature, resuspended in 3% glutaraldehyde at
pH 7.4 for 2h then centrifuged for 10min at 100g.
The resulting pellet was post-fixed for I h in 1%
osmium tetroxide (Johnson Matthey, England).
After washing in 0.135 M phosphate buffer, cells
were resuspended in melted agar which was allowed
to harden at 4°C. The agar was cut into blocks,
dehydrated in increasing concentrations of ethanol,
suspended in epoxypropane (BDH, England) at
room temperature then impregnated and set in
Polarbed/Araldite (Polaron, England). Thin sections
were cut on a Reichert OMU-4 microtome and
mounted on G300 grids (Polaron, England). Semi-
thin sections were cut from the resin-embedded
material and stained with 1% methylene blue in
1% borax and azure A in distilled water. The
sections were viewed with a Philips EM300
transmission electron microscope.
Results
Specificity of high and low dose glucocorticoid
cytolethal response
Cell type specificity
High (suprapharmacological) doses of MPSS
(10-3 M) produce virtually identical lethal effects in
both glucocorticoid-sensitive and -insensitive HLCL
and human fibroblasts (Table I). At low
(pharmacological) concentrations of hormone
(10-6M) only the sensitive HLCL (CCRF-CEM-
C7) shows significant cytolethal responses (>75%
cells killed after 96h treatment).
Table I Cell type specificity: cytolethal response*
Methyl % viability after steroid
Prednisolone treatment ofcell lines.
Concentration
(M) CCRF-CEM CCRF-CEM-C7 Flow 100
10-3 <25% <25% <25%
10-6 >90% <25% >90%
*Cytolethal response following treatment with steroid for
96h as assessed by nigrosine exclusion (0.25%).
Steroid specificity
As shown in Table II with suprapharmacological
concentrations of hormone (10-3 M) both HLCL
and fibroblasts manifest marked cytolethal
responses irrespective of the class of steroid
employed. By contrast, at low steroid
concentrations (10-6 M), cytolethal responses are
observed only with active glucocorticoids
prednisolone, dexamethasone and triamcinolone
in the sensitive HLCL (CCRF-CEM-C7).GLUCOCORTICOID-INDUCED LYMPHOID CELL DEATH 479
Table II Steroid specificity: cytolethal response*
% viability after steroid
Steroidt treatment ofcell lines:
Concentration
(M) CCRF-CEM CCRF-CEM-C7 Flow 1000
10-3 <25% <25% <25%
10-6 >90% <25%§ >90%
*Cytolethal response following treatment with various
steroids for 96h as assessed by nigrosine exclusion (0.25%).
tPrednisolone, dexamethasone, triamcinolone,
cortexolone, prednisone, spironolactone, testosterone,
progesterone.
§Prednisolone, dexamethasone, triamcinolone only.
Kinetics ofcytolethal response
HLCL treated with water alone, show a 6-fold
increase in viable cell concentration over the 96h
treatment period (Figure 1). When exposed to
suprapharmacological concentrations of MPSS
(10-s M) both glucocorticoid-sensitive (CCRF-
CEM-C7) and -insensitive (CCRF-CEM) cell lines
show immediate loss of proliferative capacity and
by 48 h nearly all cells are dead (Figure 1). By
contrast, in the presence of pharmacological
concentrations of hormone (10-6 M), CCRF-CEM-
C7 cells initially show comparable growth to
controls with 2 to 3-fold increase in number of
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viable cells. However, lethal effects ensue 24-36h
after commencement of steroid treatment and
rapidly progress until 96h when only a few viable
cells remain. No cytolethal or cytostatic effects are
observed in CCRF-CEM cells treated with
pharmacological concentrations (10-6M) of MPSS
(Figure 1).
Pulsedglucocorticoid treatment
Glucocorticoid therapy of human leukaemias and
lymphomas is discontinuous and comprises
repeated daily pulses of hormone. Assuming
equilibration of hormone within body fluid
compartments is equal and non-concentrative and
the half-life of prednisolone is about 200min
(Wode, 1977), pharmacological doses of
prednisolone should achieve in vivo concentrations
of 10-6 M for up to 6h following each treatment.
To stimulate such therapeutic practices gluco-
corticoid-sensitive lymphoid cells (CCRF-CEM-C7)
were exposed to repeated 3 or 6h daily pulses of
MPSS at constant times each day. Employing this
procedure the cytolethal response observed with
continuous 10 6 M MPSS treatment is completely
abolished (Figure 2).
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Figure 1 Growth of glucocorticoid-insensitive
(CCRF-CEM) (-) and -sensitive (CCRF-CEM-C7)
lymphoid cells in presence of high (10-3 M) and
low (10-6 M) doses of MPSS. Interrupted line
represents both insensitive and sensitive cells treated
with water alone. Cell viability was assessed at 0, 48
and 96h by exclusion of nigrosine (0.25%).
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Figure 2 Growth of glucocorticoid-sensitive (CCRF-
CEM-C7) lymphoid cells in presence of pulsed (3 or
6h daily) or continuous treatment with 106M MPSS.
Cell viability was assessed at 0, 48 and 96h by
exclusion of nigrosine (0.25%).
Duration of glucocorticoid treatment and cytolethal
response
The duration of continuous treatment of
glucocorticoid-sensitive lymphoid cells (CCRF-480 R.W. BLEWITT et al.
CEM-C7) with low doses of MPSS (10-6M) was
varied by washing cells free of steroid at selected
time intervals up to 96h after commencement of
treatment; cells were subsequently grown in steroid-
free medium until completion of the experiment.
The duration of glucocorticoid treatment is directly
proportional to the magnitude of cytolethal
response observed (Figure 3). Treatment for 24h or
less results in complete loss of lethal responses with
growth of cells continuing in an identical fashion to
untreated controls.
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Figure 3 Growth of glucocorticoid-sensitive (CCRF-
CEM-C7) lymphoid cells after varying the duration of
exposure to 10-6M MPSS. Treatment was terminated
at the specified times by washing cells free of steroid.
Cell viability was assessed at 0, 48 and 96h by
exclusion of nigrosine (0.25%).
Morphology of cell death induced by high and low
doses ofglucocorticoid
The sequence of morphological changes following
glucocorticoid treatment was studied by phase-,
light- and electron-microscopy. The morphological
sequence induced with high (10-3 M) or low
(10-6 M) concentrations of glucocorticoid is
identical irrespective of the cell type involved.
Similar changes are seen also in cells dying as a
result of deliberate feed exhaustion. Changes occur
asynchronously within individual cultures and
apparently unaffected cells co-exist for long periods
(up to 72h) alongside cells exhibiting advanced
lethal changes.
The earliest changes comprise loss of the normal
irregular surface contour (Figure 4) with rounding-
up of cells and the formation of a crescent or ring
of condensed chromatin along the inner margin of
the nuclear membrane (Figure 5). Once initiated
chromatin condensation progresses swiftly until
virtually the whole nucleus is affected. These
changes are first evident in a small proportion of
glucocorticoid-sensitive lymphoid cells (CCRF-
CEM-C7) 24h after treatment with low doses of
glucocorticoid (10-6M) but are seen after 6h in
both glucocorticoid-sensitive and -insensitive cells
when high doses of hormone (10-3M) are used.
HLCL normally contain multiple nucleoli (Figure
4) although these are not usually conspicuous
ultrastructurally until their chromatin investment is
shed following steroid treatment. They do not
appear to change location within the nucleus in
these circumstances (Figures 6 and 7). Once
chromatin condensation is evident fluid
accumulation commences within mitochondria and
other cytoplasmic organelles and rapidly extends to
involve the whole cytoplasm (Figure 8). Dense
chromatin bodies are formed and cells begin to
fragment. The precise duration of this sequence
cannot be determined accurately because of the
asynchronous nature of the response but it appears
to take about 48h for completion.
Nearly one-third of dying cells exhibit a further
morphological feature. This is seen principally in
fresh cell suspensions and smears and is rarely
evident in cytospin preparations or sections
prepared from resin-embedded material. It
comprises formation of multiple large blunt-
surfaced protrusions which in some cases are so
marked that cells assume a distorted clover-leaf
shape (Figures 9 and 10). Feulgen staining reveals
that, in addition to cytoplasm, most of these
protrusions contain uncondensed (dispersed) DNA.
This phenomenon is virtually restricted to cells no
longer capable of excluding vital dyes and showing
chromatin condensation and nuclear shrinkage. It is
not restricted to glucocorticoid-sensitive cells and
may be seen also in glucocorticoid-insensitive cells
following high dose (10-3M) steroid treatment as
well as cell lines where death is induced by
deliberate feed exhaustion.
Discussion
These studies show that high (10 M) and low
(10-6 M) doses of steroid induce cytolethal
responses that differ markedly in terms of kinetics
and specificity. High (suprapharmacological) doses
of steroid induce changes that are neither cell type
nor steroid specific. It is possible that any steroid at
this concentration will induce cytolethal responses
in any type of cell. It is doubtful therefore, if the in
vitro model studied previously (Robertson et al.,
1978) has any clinical relevance. By contrast theGLUCOCORTICOID-INDUCED LYMPHOID CELL DEATH
Figure 4 Transmission electron micrograph (TEM) of untreated CCRF-CEM-C7 cell. The cell surface is
irregular and shows few villous processes. The nucleus is convoluted and the nucleolus (arrow) is almost
hidden by associated heterochromatin. Uranyl acetate and lead citrate (UALC) x 9,760.
Figure 5 TEM of CCRF-CEM-7 cell after 32h treatment with 10-6 M MPSS. It shows the earliest
observable changes of impending cell death: chromatin condensation and margination and rounding of the
cell surface. Fluid accumulation is not yet evident. UALC x 11,900.
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Figure 6 TEM of CCRF-CEM-C7 cell after 32h treatment with 10-6M MPSS. There is margination of
nuclear chromatin and the nucleolus is readily discernible (arrow). Some mitochondria show fluid
accumulation. UALC x 11,900.
.I
Figure 7 TEM of CCRF-CEM-C7 cell after 48h treatment with 10-6M MPSS. Chromatin condensation
has revealed two structures resembling nucleoli (arrows). Cytoplasmic fluid accumulation is now apparent.
UALC x 17,950.GLUCOCORTICOID-INDUCED LYMPHOID CELL DEATH
Figure 8 TEM of CCRF-CEM-C7 cell after 48h treatment with 10-6 M MPSS. It shows a late stage of the
cytolethal process with gross waterlogging and disintegration of cytoplasm and fragmentation of condensed
masses of chromatin. UALC x 11,900.
Figure 9 Smear preparation of CCRF-CEM-C7 cell after 48 h treatment with 10-6 M MPSS. The cell
exhibits pronounced formation of surface protrusions. Giemsa x 5.625.
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Figure 10 TEM of CCRF-CEM-C7 cell after 48h treatment with 10-6M MPSS. Cytoplasmic protrusion
(P), rarely seen in ultra-thin preparations, appears dense in comparison with waterlogged remainder of
cytoplasm. The base of the protrusion is closely associated with a mass of condensed chromatin. UALC x
17,950.
low (pharmacological) dose effect, restricted to the
sensitive lymphoid cell line (CCRF-CEM-C7)
requires an active glucocorticoid and a hormone
concentration (10-6M) that may be achieved
during therapy. This concentration, however, still
exceeds that required to saturate cytoplasmic
glucocorticoid receptors (Barrett et al., 1981) and
maximum physiological hormone levels (10-'M)
which in these cell lines fails to induce cytolethal or
cytostatic responses even when cells are
continuously exposed to steroid for prolonged
periods (up to 28 days). However, it seems likely
the mode of action of glucocorticoids in vivo is
complex and may involve both direct cytolethal
actions as well as secondary effects mediated
through influences on levels of growth factors
(interleukins) and other mechanisms (Bird, 1979;
Gillis et al., 1979; Krajewski & Wyllie, 1981;
Paetkau, 1981). The relatively higher concentration
of glucocorticoid required for induction of
cytolethal responses in vitro may reflect the absence
of such secondary influences.
Despite the difference in kinetics and specificity
of high and low dose steroid effects the morphology
of cell death in each case appears identical and
closely resembles that described previously in
glucocorticoid-resistant HLCL treated with high
doses of steroid (Robertson et al., 1978). Similar
changes were also observed in cultures where cells
were deliberately killed by feed exhaustion. Many
of the ultrastructural changes observed resemble
those described in apoptosis (Kerr et al., 1972) the
form of cell death occurring in vivo where cell
deletion is considered programmed (Wyllie et al.,
1980). Although morphologically similar it seems
unlikely that the intracellular events associated
with apoptosis will be strictly comparable to those
where cell death may be non-specific. Nonetheless
HLCL remain valuable in vitro models for studying
the effects of glucocorticoids on human lymphoid
cells so long as pharmacologically-relevant
concentrations of hormone (10-6 M) are employed,
although the relevance for apoptosis of any changes
demonstrated remains to be established.
Whatever nomenclature is applied to this form of
cell death one of the earliest morphological features
following glucocorticoid treatment is condensation
of nuclear chromatin. Absence of demonstrable
intermediate stages between early and late phases of
this process suggests that once induced such
changes progress rapidly. Normally chromatin is
closely apposed and probably attached to theGLUCOCORTICOID-INDUCED LYMPHOID CELL DEATH 485
supporting protein substructure of the nucleus,
termed the nuclear matrix (Agutter & Richardson,
1980). Margination and condensation of chromatin
implies either the nuclear matrix marginates or that
chromatin becomes detached from it. The failure of
nucleoli to change location within the condensed
nuclei suggests the matrix remains unaltered and
that condensation of chromatin results from the
physical detachment of chromatin from the
underlying matrix. There is evidence from studies
with rat thymocytes treated with low doses of
glucocorticoid that condensed chromatin is rapidly
broken into short nucleosome chains by
endogenous endonuclease (Wyllie, 1980). It is not
known whether this process is responsible also for
the detachment of chromatin from the nuclear
matrix or indeed what protects chromatin from
endonucleases normally present in the nucleus.
Activation of these endogenous enzymes may
represent the first crucial step in the final common
pathway of cytolethal responses.
The cause of the large surface protrusions seen in
fresh suspensions and smears of glucocorticoid-
treated cells is unknown. They are apparently
delicate structures since they do not easily survive
processing schedules and are found only with any
frequency in fresh cell preparations. It is important
to note they can also be induced artefactually in
cells by over-vigorous smearing. They are probably
not an early feature of cell death since cells
manifesting these structures are permeable to vital
dyes and show extensive condensation of nuclear
chromatin. The demonstration of large amounts of
Feulgen-positive material within protrusions
suggests released DNA or other nuclear contents
may play a part in their production. This might be
achieved through some interaction with the
cytoskeleton causing cell deformation.
Alternatively, steroids may induce focal defects in
the plasma membrane through which cytoplasmic
contents may protrude. It is of interest therefore
that apparent defects or 'holes' have been observed
by scanning electron microscopy (SEM) in the
plasma membrane of chronic lymphocytic
leukaemia cells treated with glucocorticoids (Galili
et al., 1982). We have also observed similar
membrane defects in SEM studies of our cell lines
following steroid treatment (manuscript in
preparation).
Induction of cytolethal effects with low
(pharmacological) doses of glucocorticoid in the
sensitive HLCL appears to require the continuous
presence of steroid for over 24h. Discontinuous 3-
6h daily pulses of glucocorticoid, comparable to
therapeutic practices, proved ineffective in inducing
cytolethal responses. Although the clinical relevance
of this in vitro model of glucocorticoid-induced cell
death requires further substantiation, the possibility
that current therapeutic regimens may not be
optimal for achieving maximal clinical responses
should be considered. The timing of administration
of other drugs used in combination with
glucocorticoids also needs careful consideration
(Gledhill & Norman, 1981).
A constant feature of the low dose glucocorticoid
response is the initial 24-36h latent interval prior
to the onset of cytolethal effects. Briefer steroid
exposure leaves cells apparently unscathed with
growth rates indistinguishable from that of
untreated controls. Further continuous exposure to
steroid invariably leads to cell death in an
asynchronous but steadily progressive manner until
virtually every cell is affected by 96h. The critical
intracellular events leading to the ultimate
commitment to cell death are unknown but may
relate to the progressive arrest of cells in the GI
phase of the cell cycle (Harmon et al., 1979). Since
transition from Gl to S phase of the cell cycle
represents a critical point of cell cycle regulation
(Shields, 1977; Robinson et al., 1976) it seems
possible that glucocorticoids progressively interfere
with replication control at this stage. Further
investigation of changes occurring within the first
24-36h following steroid treatment clearly holds the
key to understanding the mechanisms by which
glucocorticoids induce cytolethal responses in
human lymphoid cells.
This work is supported by a grant to C.C. Bird from the
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